<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04440891</url>
  </required_header>
  <id_info>
    <org_study_id>1904522298</org_study_id>
    <nct_id>NCT04440891</nct_id>
  </id_info>
  <brief_title>Application of TMS Coupled With VR for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease</brief_title>
  <acronym>TMS_AD</acronym>
  <official_title>Application of Transcranial Magnetic Stimulation Coupled With Virtual Reality for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ali Rezai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Virginia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized sham control study to evaluate how repetitive Transcranial Magnetic
      Stimulation (rTMS), interactive cognitive training, or the combination of rTMS and cognitive
      training reduce the cognitive decline of patients diagnosed with Alzheimer's disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants may be assigned to one of four experimental arms (1-TMS-Stimulation with X-Torp
      task, 2-TMS-Stimulation with MindMotion Go, 3-TMS-Sham with X-Torp task, 4-TMS-Sham with
      MindMotion Go.) The study will be conducted in two phases. During Phase 1, participants will
      be randomized between experimental conditions 1 and 4. Data will be analyzed upon completion
      of Phase1 and Phase 2 will commence only if there is efficacy in the TMS arm. During Phase2,
      participants will be randomized to arms 2 and 3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Performance</measure>
    <time_frame>6 months after completion study procedure</time_frame>
    <description>Change in cognitive task performance over time using the total score on the Mini Mental State Examination (range 0-30)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain MRI</measure>
    <time_frame>6 months after completion of study procedure compared to screening</time_frame>
    <description>Change in brain structure and function over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory Performance</measure>
    <time_frame>6 months after completion of study procedure compared to screening</time_frame>
    <description>Total recall on the California Verbal Learning Test - short form (range 0-36)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>TMS-Stimulation with X-Torp task</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMS with VR 1 experimental arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMS-Stimulation with MindMotion Go</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMS with VR 2 experimental arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMS-Sham with X-Torp task</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>TMS sham control with VR 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMS-Sham with MindMotion Go</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>TMS sham control with sham VR 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS stimulation with X-Torp task</intervention_name>
    <description>TMS-Stimulation with X-Torp task</description>
    <arm_group_label>TMS-Stimulation with X-Torp task</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS-Stimulation with MindMotion Go</intervention_name>
    <description>TMS-Stimulation with MindMotion Go</description>
    <arm_group_label>TMS-Stimulation with MindMotion Go</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS-Sham with X-Torp task</intervention_name>
    <description>TMS-Sham with X-Torp task</description>
    <arm_group_label>TMS-Sham with X-Torp task</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS-Sham with MindMotion Go</intervention_name>
    <description>TMS-Sham with MindMotion Go</description>
    <arm_group_label>TMS-Sham with MindMotion Go</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or Female between 50-85 years of age

          -  Able and willing to give informed consent

          -  Probable AD consistent with NIA/AA criteria

          -  Modified Hachinski Ischemia Scale (MHIS) score of &lt;= 4

          -  Geriatric Depression Scale (GDS) score of &lt;= 6

          -  Mini Mental State Exam (MMSE) score 18-26. The MMSE adjusted scoring instructions may
             be followed for screening patients as applicable.

        Exclusion Criteria:

          -  Unstable medical conditions

          -  Visual impairments

          -  Mobility limitations

          -  Cognition-enhancing medication unless on a stable dosage for at least 3 months before
             the start of the trial.

          -  History of epilepsy or seizure disorder

          -  History of psychosis

          -  Current thoughts of suicidal ideation or self-harm as assessed by the Columbia-Suicide
             severity rating scale score

          -  Progressive neurological disorder or focal signs of abnormality on neurological exam
             as conducted by a neurologist (other than current diagnosis of AD)

          -  Tinnitus

          -  Metal implants (excluding dental fillings)

          -  Possible pregnancy

          -  Substance use disorder within the past six months

          -  Have other mental or physical conditions that are inappropriate for study
             participation at PI's or delegated sub investigator's discretion.

          -  Intake of one or a combination of the drugs that may due to their significant seizure
             threshold lowering potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Haut, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rockefeller Neuroscience Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor Finomore, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Rockefeller Neuroscience Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Harring</last_name>
    <phone>3042939638</phone>
    <email>barbara.harring@hsc.wvu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Padma Tirumalai, PhD</last_name>
    <phone>3042934999</phone>
    <email>ptirumalai@hsc.wvu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West Virginia University Rockefeller Neuroscience Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc W Haut, PhD</last_name>
      <phone>304-293-6276</phone>
      <email>mhaut@hsc.wvu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Harring</last_name>
      <phone>304-293-9638</phone>
      <email>barbara.harring@hsc.wvu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>West Virginia University</investigator_affiliation>
    <investigator_full_name>Ali Rezai</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

